Volume | 53 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aditxt Inc | ADTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.53 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
9 | 53 | - | 2.14 - 68.08 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
06:52:17 | 10 | $ 2.37 | USD |
Aditxt Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
4.21M | 1.67M | - | 934k | -27.65M | -16.60 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aditxt News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ADTX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.48 | 2.69 | 2.14 | 2.42 | 62,363 | 0.05 | 2.02% |
1 Month | 3.38 | 5.09 | 2.14 | 3.30 | 812,026 | -0.85 | -25.15% |
3 Months | 3.74 | 5.09 | 2.14 | 3.39 | 331,153 | -1.21 | -32.35% |
6 Months | 7.70 | 9.50 | 2.14 | 5.41 | 832,337 | -5.17 | -67.14% |
1 Year | 27.60 | 68.08 | 2.14 | 10.28 | 592,591 | -25.07 | -90.83% |
3 Years | 105.60 | 1,139.60 | 2.14 | 49.05 | 2,264,397 | -103.07 | -97.60% |
5 Years | 211.20 | 1,139.60 | 2.14 | 72.66 | 2,209,902 | -208.67 | -98.80% |
Aditxt Description
Aditxt Inc is a life sciences company which focuses on prolong life and enhance life quality of transplanted patients. The firm develop products designed to induce tolerance to transplanted organs. The firm's immunosuppressive (anti-rejection) drugs has made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues. |